Evidence map›Paper›PMID 31382785›Full record

ArticleExpert opinion on biological therapy2019

Immune therapy, a double-edged sword for oncolytic viruses.

Ryan M McCormack, Balveen Kaur

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Expert opinion on biological therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ryan M McCormackDepartment of Neurosurgery, McGovern Medical School, University of Texas Health Science Center at Houston , Houston , TX , USA.
Balveen KaurDepartment of Neurosurgery, McGovern Medical School, University of Texas Health Science Center at Houston , Houston , TX , USA.

Funding

The Tumor Microenvironmental Barrier to Effective Viral OncolysisP01CA163205 · NCI · OHIO STATE UNIVERSITY · PI KEITH LLOYD LIGON · 2013 to 2026
$26.0M
Enhancing Viral Oncolysis with Vasculostatin Gene DeliveryR01CA150153 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KAUR, BALVEEN · 2011 to 2020
$4.0M
OV Therapy Induced Changes in Tumor Secretome and Their Impact on TherapyR01NS064607 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KAUR, BALVEEN · 2008 to 2018
$3.2M
Optimizing oncolytic virus therapy for glioblastomaR61NS112410 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KAUR, BALVEEN · 2019 to 2020
$775k
NCI NIH HHS P01 CA163205NCI NIH HHS R01 CA150153NINDS NIH HHS R01 NS064607NINDS NIH HHS R61 NS112410
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

immunityOncolytic virusestumor associated macrophagestumor microenvironment

Identifiers

PMID31382785
PMCPMC6863343

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.